Despite the powerful effects exerted by these somatic mutations in Keap1 or Nrf2 that lead to the constitutive activation of Nrf2, such mutations were only found in ~1.45% of all cancer samples examined in studies published in COSMIC 2018 (COSMIC; http:// cancer.sanger.ac.uk/cosmic). This evidence concerns the gene NFE2L2 and cancer.